Patents by Inventor Jason Goodrich

Jason Goodrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MACROCYCLIC PEPTIDES USEFUL AS MODULATORS OF TNF ALPHA
    Publication number: 20250145665
    Abstract: Disclosed are macrocyclic peptide compounds or a salt thereof, which are useful as modulators of TNF?, and pharmaceutical compositions comprising such compounds. These compounds may be useful in treating cancers, inflammatory and autoimmune diseases.
    Type: Application
    Filed: July 31, 2024
    Publication date: May 8, 2025
    Inventors: Yong Zhang, Alaric J. Dyckman, Ving G. Lee, Zheming Ruan, Jason Goodrich, Lidet A. Negash, Saleem Ahmad, Hong Wu, John Hynes, Michael A. Poss, Alexander C. Brueckner, Sirish Kaushik Lakkaraju
  • Immunomodulators
    Patent number: 11952434
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: April 20, 2022
    Date of Patent: April 9, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
  • IMMUNOMODULATORS
    Publication number: 20230101323
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: April 20, 2022
    Publication date: March 30, 2023
    Applicant: Bristol-Myers Squibb Company
    Inventors: Kevin W. GILLMAN, Jason GOODRICH, Kenneth M. BOY, Yunhui ZHANG, Claudio MAPELLI, Michael A. POSS, Paul Michael SCOLA, David R. LANGLEY, Nicholas A. MEANWELL
  • Immunomodulators
    Patent number: 11358988
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: June 14, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
  • Immunomodulators acting as antagonists of PD-1
    Patent number: 11066445
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: July 20, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kevin W. Gillman, Jason Goodrich, Li-Qiang Sun, Eric Mull, David R. Langley, Paul Michael Scola
  • Immunomodulators
    Patent number: 10988507
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: April 27, 2021
    Assignee: bristol-myers squibb company
    Inventors: Kevin W. Gillman, Jason Goodrich, David R. Langley, Paul Michael Scola
  • IMMUNOMODULATORS
    Publication number: 20200216498
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: December 11, 2019
    Publication date: July 9, 2020
    Applicant: Bristol-Myers Squibb Company
    Inventors: Kevin W. GILLMAN, Jason GOODRICH, Kenneth M. BOY, Yunhui ZHANG, Claudio MAPELLI, Michael A. POSS, Paul Michael SCOLA, David R. LANGLEY, Nicholas A. MEANWELL
  • IMMUNOMODULATORS ACTING AS ANTAGONISTS OF PD-1
    Publication number: 20200172578
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 pro-tein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: June 21, 2018
    Publication date: June 4, 2020
    Applicant: Bristol-Myers Squibb Company
    Inventors: Kevin W. GILLMAN, Jason GOODRICH, Li-Qiang SUN, Eric MULL, David R. LANGLEY, Paul Michael SCOLA
  • Immunomodulators
    Patent number: 10633419
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: April 28, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
  • IMMUNOMODULATORS
    Publication number: 20190322704
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: November 6, 2017
    Publication date: October 24, 2019
    Inventors: Kevin W. GILLMAN, Jason GOODRICH, David R. LANGLEY, Paul Michael SCOLA
  • IMMUNOMODULATORS
    Publication number: 20180086793
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: November 27, 2017
    Publication date: March 29, 2018
    Inventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
  • Immunomodulators
    Patent number: 9856292
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: January 2, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
  • Hepatitis C virus inhibitors
    Patent number: 9758487
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: September 12, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Gan Wang, Lawrence G. Hamann
  • Hepatitis C Virus Inhibitors
    Publication number: 20160311778
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Application
    Filed: June 28, 2016
    Publication date: October 27, 2016
    Inventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Gan Wang, Lawrence G. Hamann
  • Immunomodulators
    Publication number: 20160137696
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: November 11, 2015
    Publication date: May 19, 2016
    Inventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
  • Hepatitis C virus inhibitors
    Patent number: 9227961
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: January 5, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Lawrence G. Hamann
  • Hepatitis C virus inhibitors
    Patent number: 9018390
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: April 28, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Lawrence G. Hamann
  • Hepatitis C Virus Inhibitors
    Publication number: 20150011754
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Application
    Filed: September 17, 2014
    Publication date: January 8, 2015
    Inventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Lawrence G. Hamann
  • Hepatitis C virus inhibitors
    Patent number: 8846023
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: September 30, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Gan Wang, Lawrence G. Hamann
  • Path-based crosstalk fault test scanning in built-in self-testing
    Patent number: 8788897
    Abstract: A path-based crosstalk fault model is used in conjunction with a built-in self-test (BIST) and software capability for automatic test pattern generation. The solution allows for test patterns to be generated that maximize switching activity as well as inductive and capacitive crosstalk. The path based fault model targets the accumulative effect of crosstalk along a particular net (“victim” path), as compared with the discrete nets used in conventional fault models. The BIST solution allows for full controllability of the target paths and any associated aggressors. The BIST combined with automatic test pattern generation software enables defect detection and silicon validation of delay defects on long parallel nets.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: July 22, 2014
    Assignee: Texas Instruments Incorporated
    Inventors: Nisar Ahmed, Corey Jason Goodrich, Xiao Liu, Chris Therrien